全文获取类型
收费全文 | 1152篇 |
免费 | 50篇 |
国内免费 | 8篇 |
学科分类
医药卫生 | 1210篇 |
出版年
2017年 | 10篇 |
2015年 | 6篇 |
2014年 | 12篇 |
2013年 | 18篇 |
2012年 | 13篇 |
2011年 | 16篇 |
2010年 | 44篇 |
2009年 | 38篇 |
2008年 | 15篇 |
2007年 | 15篇 |
2006年 | 32篇 |
2005年 | 12篇 |
2003年 | 10篇 |
2000年 | 6篇 |
1999年 | 11篇 |
1998年 | 28篇 |
1997年 | 33篇 |
1996年 | 29篇 |
1995年 | 21篇 |
1994年 | 28篇 |
1993年 | 20篇 |
1992年 | 25篇 |
1991年 | 18篇 |
1990年 | 17篇 |
1989年 | 27篇 |
1988年 | 18篇 |
1987年 | 17篇 |
1986年 | 13篇 |
1984年 | 9篇 |
1983年 | 17篇 |
1982年 | 6篇 |
1981年 | 6篇 |
1980年 | 8篇 |
1978年 | 7篇 |
1977年 | 7篇 |
1976年 | 8篇 |
1975年 | 5篇 |
1972年 | 6篇 |
1970年 | 8篇 |
1964年 | 8篇 |
1963年 | 11篇 |
1959年 | 51篇 |
1958年 | 77篇 |
1957年 | 75篇 |
1956年 | 75篇 |
1955年 | 66篇 |
1954年 | 57篇 |
1949年 | 35篇 |
1948年 | 44篇 |
1946年 | 10篇 |
排序方式: 共有1210条查询结果,搜索用时 31 毫秒
1.
2.
JAE YOUNG JOUNG DONG GOO KANG HYUCK-JAE CHOI WEON SEO PARK HO KYUNG SEO JIN SOO CHUNG KANG HYUN LEE 《International journal of urology》2006,13(11):1451-1453
Abstract Gastrointestinal stromal tumor (GIST) is a recently described mesenchymal tumor that can develop in any portion of the gastrointestinal tract. The occurrence of a GIST in the urinary tract is rare, but GIST can present as tumor of the urinary tract or invade the urinary tract. This is the first reported case of GIST in the ileal neobladder, which presented as a submucosal tumor. The patient underwent an open exploration and partial resection of the neobladder pouch. 相似文献
3.
4.
5.
6.
7.
8.
COMPARISON OF THORACIC ELECTRICAL BIOIMPEDANCE AND THERMODILUTION FOR THE MEASUREMENT OF CARDIAC INDEX IN PATIENTS WITH SEVERE SEPSIS 总被引:5,自引:1,他引:4
Cardiac index was measured using thoracic bioimpedance (Clbi)and thermodilution (Cltd) in 19 patients with proven sepsis,undergoing artificial ventilation of the lungs. There was apoor correlation between the techniques (r = 0.36, 242 datasets, regression line Clbi = 0.16 Cltd + 2.56 litre min1m2). The overall bias (Cltd-Clbi) was 1.69 litre min1m2 with limits of agreement (precision) of +4.17 to 0.79litremin1 m2. In individual patients the bias was from0.46 to 4.56 litre min1 m2 with the limits of agreementfrom ±0.29 to ±2.55 litre min1 m2around the bias values. The two techniques cannot be used interchangeablyin this group of patients. (Br. J. Anaesth. 1993; 70: 5862)
*Present address, for correspondence: Nuffield Department ofAnaesthetics, Radcliffe Infirmary, Woodstock Road, Oxford OX26HE 相似文献
9.
WHAN KOOK CHUNG KYU YONG CHOI CHANG DON LEE JIN WU CHUNG HEE SIK SUN KYU WON CHUNG BOO SUNG KIM CHUNG SIK CHUN KYOO HONG CHO SEUNG JO KIM 《Journal of gastroenterology and hepatology》1987,2(1):13-17
Different doses of hepatitis B virus vaccine—prepared by Korea Green Cross Corporation, were given to healthy infants born to HBsAg-negative mothers at birth, 1 and 6 months of age. A dose of 2 μg was administered intradermally in Group A and, in the three other groups, the vaccine was given intramuscularly (i.m.). An adequate follow-up observation was possible for 9 months after birth in 22, 25, 23 and 21 infants in Groups A, B, C and D, respecvely.
Group C (5 μg, i.m.) produced seroconversion most rapidly, showing the highest rate (96%) at 9 months of age. The lowest seroconversion rate (5%) was found at the age of 1 month in Group A subjects, but the rate increased to 91% after a booster dose was given at 6 months of age.
While it can be concluded that a 5 μg i.m. dose of vaccine at 0, 1 and 6 months of age is optimum for the immunization of infants in efficacy and economy, a 2 μg intradermal dose can also be considered as an immunogenic and economical regimen, though the immune response is slower and a special technique is required for immunization. 相似文献
Group C (5 μg, i.m.) produced seroconversion most rapidly, showing the highest rate (96%) at 9 months of age. The lowest seroconversion rate (5%) was found at the age of 1 month in Group A subjects, but the rate increased to 91% after a booster dose was given at 6 months of age.
While it can be concluded that a 5 μg i.m. dose of vaccine at 0, 1 and 6 months of age is optimum for the immunization of infants in efficacy and economy, a 2 μg intradermal dose can also be considered as an immunogenic and economical regimen, though the immune response is slower and a special technique is required for immunization. 相似文献
10.
LEE JS IM HH JUNG Y JUNG IS JANG JY CHUN YK CHO YD KIM JO CHO JY KIM YS SHIM CS & KIM BS 《Neurogastroenterology and motility》2006,18(6):493-494
Background: Recent development of extracorporeal magnetic stimulation (ECMS) which uses current‐changing magnetic fields allows the induction of electrical stimulation in the desired deep tissue. Recent study showed the sacral nerve stimulation reduces corticoanal excitability that may play a functional role in anal continence mechanisms. Preliminary study shows that ECMS of sacral nerve can modify pelvic floor function and expel rectal balloon in patients with pelvic floor dyssynergia (PFD). Aims: To evaluate the effect of ECMS compared with biofeedback therapy (BF) in patients with PFD. Methods and Materials: Thirty‐eight patients who fulfilled Rome II criteria for PFD by colon transit time and anorectal function tests, were randomly treated with 8 sessions of ECMS (2/weeks; n = 19) at prone position or BF (2/weeks; n = 19) at sitting position. Stimulation parameters were set at 50–80% of maximum intensity, 10 and 50 Hz frequency, 3 s burst length with 3 and 6 s off using arm‐typed stimulator (BioCom‐1000, Mcube Co., Korea). Symptom scores for constipation with/without anorectal function test were repeatedly measured after each treatment. Response was defined as 50% or more decreased symptom score after treatment (partial response: 30–50%, poor: <30%). Results: Fifteen patients (age 49.1 ± 13.4 years, mean ± SD; 4 men) completed 8 session of BF and 14 patients (54.5 ± 17.6 years, 3 men) completed 8 session of ECMS. Four patients of BF group discontinued treatment due to unsatisfactory therapeutic effect (n = 1) and withdrew consent (n = 3) and 5 patients of ECMS group discontinued treatment because of same reasons (n = 1, 4). Total symptom scores were significantly decreased after treatment of 8 session in both treatment groups (13.4 ± 6.6 vs. 4.3 ± 4.0 for BF, p = 0.009; 14.9 ± 5.6 vs. 3.4 ± 4.0 for ECMS, p < 0.001). Bowel movements per week were also significantly increased after treatment in both groups (median 2 vs. 7 for BF, p = 0.035; median 2 vs. 7 for ECMS, p = 0.008). Thirteen out of 15 patients showed response in BF group and 12 out of 14 showed good response in ECMS group. No adverse effects in both groups. Conclusions: ECMS is as effective as BF for the treatment of PFD. Long‐term effect of ECMS for the patients with pelvic floor dyssynergia need to be evaluated in the near future. 相似文献